

Transplantation, Healthcare Systems Bureau, HRSA, 5600 Fishers Lane, Room 08W60, Rockville, Maryland 20857; 301-443-6839; or [rwalsh@hrsa.gov](mailto:rwalsh@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** The ACOT provides advice and recommendations to the Secretary of HHS (Secretary) on all aspects of organ donation, procurement, allocation, and transplantation, and on such other matters that the Secretary determines. ACOT is authorized by 42 U.S.C. 217a; Section 222 of the Public Health Service Act, as amended; 42 CFR 121.12.

The Committee is governed by provisions of the FACA, Public Law 92-463 (5 U.S.C. App. 2), which sets forth standards for the formation of advisory committees. The recommendations of the ACOT inform HHS programs and activities to support organ donation and transplantation. ACOT's recent recommendations in support of expanding reimbursement of living organ donor expenses were cited as a key part of the rationale for recent proposed HHS actions to expand this activity consistent with the President's Executive Order on Advancing American Kidney Health. The charter renewal for the ACOT was approved on August 31, 2020, which will also stand as the filing date. Renewal of the ACOT charter gives authorization for the committee to operate until August 31, 2022.

A copy of the ACOT charter is available on the ACOT website at <https://www.organdonor.gov/about-dot/acot.html>. A copy of the charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is <http://www.facadatabase.gov/>.

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2020-19644 Filed 9-3-20; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Solicitation of Nominations for Membership To Serve on the Advisory Committee on Heritable Disorders in Newborns and Children

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

**ACTION:** Request for advisory committee member nominations.

**SUMMARY:** HRSA is seeking nominations of qualified candidates to be considered for appointment as members of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC or Committee). The Committee provides advice, recommendations, and technical information about aspects of heritable disorders and newborn and childhood screening to the Secretary of HHS (Secretary). HRSA is seeking nominations of qualified candidates for appointment to five positions on the Committee for terms of up to 4 years.

**DATES:** Written nominations for membership on the Committee must be received on or before September 22, 2020.

**ADDRESSES:** Nomination packages must be submitted electronically as email attachments to Mia Morrison, MPH at [ACHDNC@hrsa.gov](mailto:ACHDNC@hrsa.gov).

**FOR FURTHER INFORMATION CONTACT:** Mia Morrison, MPH, Maternal and Child Health Bureau, HRSA 5600 Fishers Lane, Room 18W-68, Rockville, MD 20857; 301-443-2521; or [ACHDNC@hrsa.gov](mailto:ACHDNC@hrsa.gov). A copy of the Committee charter and list of the current membership may be obtained by accessing the Committee website at <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/about/members.pdf>.

**SUPPLEMENTARY INFORMATION:** ACHDNC provides advice and recommendations to the Secretary of HHS (Secretary) on the development of newborn screening activities, technologies, policies, guidelines, and programs for effectively reducing morbidity and mortality in newborns and children having, or at risk for, heritable disorders.

In addition, the Committee provides advice and recommendations to the Secretary concerning grants, projects and technical information to develop policies and priorities for grants, including those that will enhance the ability of the state and local health agencies to provide for newborn and child screening, counseling, and health care services for newborns, and children having or at risk for heritable disorders. The Committee meets four times each calendar year, or at the discretion of the Designated Federal Officer in consultation with the ACHDNC Chair. The Committee is governed by the provisions of Federal Advisory Committee Act, as amended (5 U.S.C. App. 2), and 41 CFR part 102-3, which set forth standards for the formation and

use of advisory committees, and its Charter.

The Committee reviews and reports regularly on newborn and childhood screening practices for heritable disorders, recommends improvements in the national newborn and childhood heritable screening programs, and recommends conditions for inclusion in the Recommended Uniform Screening Panel (RUSP). The Committee's recommendations regarding additional conditions/inherited disorders for screening that have been adopted by the Secretary are included in the RUSP and constitute part of the comprehensive guidelines supported by HRSA pursuant to section 2713 of the PHS Act, codified at 42 U.S.C. 300gg-13. Under this provision, non-grandfathered health plans and group and individual health insurance issuers are required to cover screenings included in the HRSA-supported comprehensive guidelines without charging a co-payment, co-insurance, or deductible for plan years (*i.e.*, in the individual market, policy years) beginning on or after the date that is 1 year from the Secretary's adoption of the condition for screening.

#### Nominations

HRSA is requesting nominations for voting members to serve on the Committee to fill up to five positions for terms of up-to 4 years. The Secretary appoints Committee members with the expertise needed to fulfill the duties of the Advisory Committee. Nominees sought are medical, technical, or scientific professionals with special expertise in the field of heritable disorders or in providing screening, counseling, testing, or specialty services for newborns and children with, or at risk for having, heritable disorders; individuals who have expertise in ethics (*e.g.*, bioethics) and infectious diseases and who have worked and published material in the area of newborn screening; members of the public having demonstrated expertise about or concern with heritable disorders; and/or representatives from such federal agencies, public health constituencies, and medical professional societies with such expertise. Interested applicants may self-nominate or be nominated by another individual or organization. Nominees must reside in the United States and cannot be funded for international travel expenses.

Individuals selected for appointment to the Committee will be invited to serve for up-to 4 years. Members who are not federal officers or permanent federal employees are appointed as special government employees and receive a stipend and reimbursement for

per diem and travel expenses incurred for attending Committee meetings and/or conducting other business on behalf of the Committee, as authorized by section 5 U.S.C. 5703 for persons employed intermittently in government service. Members who are already officers or employees of the United States Government shall not receive additional compensation for service on the Committee, but receive per diem and travel expenses incurred for attending Committee meetings and/or conducting other business on behalf of the Committee.

The following information must be included in the package of materials submitted for each individual being nominated for consideration: (1) A statement that includes the name and affiliation of the nominee and a clear statement regarding the basis for the nomination, including the area(s) of demonstrated expertise or concern that may support eligibility of a nominee for service on the Committee, as described above; (2) confirmation the nominee is willing to serve as a member of the Committee; (3) the nominee's contact information (please include home address, work address, daytime telephone number, and an email address); and (4) a current copy of the nominee's curriculum vitae. Nomination packages may be submitted directly by the individual being nominated or by the person/organization recommending the candidate.

HHS will endeavor to ensure that the membership of the Committee is fairly balanced in terms of points of view represented and that individuals from a broad representation of geographic areas, gender, ethnic and minority groups, as well as individuals with disabilities, are considered for membership. Appointments shall be made without discrimination on the basis of age, race, color, national origin, sex, disability, or religion.

Individuals who are selected to be considered for appointment will be required to provide detailed information regarding their financial holdings, consultancies, and research grants or contracts. Disclosure of this information is required in order for HRSA to determine if the selected candidate is involved in any activity that may pose a potential conflict of interest with the official duties to be performed as a member of the Committee and to identify any required remedial action needed to address the potential conflict.

**Authority:** The ACHDNC was established under the Public Health Service (PHS) Act, 42 U.S.C. 217a: Advisory councils or

committees and Title XI § 1111(g) (42 U.S.C. 300b–10(g)).

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2020–19631 Filed 9–3–20; 8:45 am]

**BILLING CODE 4165–15–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Promoting the Rule of Law Through Improved Agency Guidance Documents

**AGENCY:** Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** On October 9, 2019, the President issued Executive Order (E.O.) 13891: Promoting the Rule of Law Through Improved Agency Guidance Document. This E.O. requires all Federal Agencies to establish an on-line guidance portal and to rescind any guidance documents that are no longer active or valid.

**SUPPLEMENTARY INFORMATION:** The Department of Health and Human Services is updating its Notice published on July 2, 2020 regarding Executive Order 13891. In that Notice, HHS made available its guidance portal which included all active guidance documents across HHS's 27 Operating and Staff Divisions. That Notice brought awareness that while many of the Centers for Medicare and Medicaid's (CMS) active guidance documents were included, it was not reflective of CMS's full inventory. OMB had granted CMS an extension until July 31, 2020 to fully populate the database to reflect CMS's full inventory of active guidance documents.

This Notice informs of an additional OMB extension granted to the Centers for Medicare and Medicaid (CMS) until September 30, 2020 to fully populate all of its inventory of active guidance documents.

**FOR FURTHER INFORMATION CONTACT:** Samuel Shipley, Executive Secretariat, at [Guidance@hhs.gov](mailto:Guidance@hhs.gov) or (202) 690–5627.

**Wilma M. Robinson,**

*Deputy Executive Secretary, Department of Health and Human Services.*

[FR Doc. 2020–19568 Filed 9–3–20; 8:45 am]

**BILLING CODE 4150–03–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Charter Renewal

In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102–3.65(a), notice is hereby given that the Charter for the National Cancer Institute Council of Research Advocates was renewed for an additional two-year period on August 17, 2020.

It is determined that the National Cancer Institute Council of Research Advocates is in the public interest in connection with the performance of duties imposed on the National Cancer Institute and National Institutes of Health by law, and that these duties can best be performed through the advice and counsel of this group.

Inquiries may be directed to Claire Harris, Acting Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail Stop Code 4875), [harriscl@nih.gov](mailto:harriscl@nih.gov) or Telephone (301) 496–2123.

Dated: September 1, 2020.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020–19619 Filed 9–3–20; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR–17–144: Limited Competition: National Primate Research Centers (P51).